Literature DB >> 17628588

Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue.

Ali El-Armouche1, Jasmin Singh, Hiroshi Naito, Katrin Wittköpper, Michael Didié, Alexander Laatsch, Wolfram-Hubertus Zimmermann, Thomas Eschenhagen.   

Abstract

PKCalpha has been shown to be a negative regulator of contractility and PKCalpha gene deletion in mice protected against heart failure. Small interfering (si)RNAs mediate gene silencing by RNA interference (RNAi) and may be used to knockdown PKCalpha in cardiomyocytes. However, transfection efficiencies of (si)RNAs by lipofection tend to be low in primary cells. To address this limitation, we developed an adenoviral vector (AV) driving short hairpin (sh)RNAs against PKCalpha (Ad-shPKCalpha) and evaluated its potential to silence PKCalpha in neonatal rat cardiac myocytes and in engineered heart tissues (EHTs), which resemble functional myocardium in vitro. A nonsense encoding AV (Ad-shNS) served as control. Quantitative PCR and Western blotting showed 90% lower PKCalpha-mRNA and 50% lower PKCalpha protein in Ad-shPKCalpha-infected cells. EHTs were infected with Ad-shPKCalpha on day 11 and subjected to isometric force measurements in organ baths 4 days later. Mean twitch tension was >50% higher in Ad-shPKCalpha compared to Ad-shNS-infected EHTs, under basal and Ca(2+)- or isoprenaline-stimulated conditions. Twitch tension negatively correlated with PKCalpha mRNA levels. In summary, AV-delivered shRNA mediated highly efficient PKCalpha knockdown in cardiac myocytes and improved contractility in EHTs. The data support a role of PKCalpha as a negative regulator of myocardial contractility and demonstrate that EHTs in conjunction with AV-delivered shRNA are a useful model for target validation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628588     DOI: 10.1016/j.yjmcc.2007.05.021

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  11 in total

Review 1.  Antisense makes sense in engineered regenerative medicine.

Authors:  Yongchang Yao; Chunming Wang; Rohan R Varshney; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

Review 2.  Myocardial tissue engineering: in vitro models.

Authors:  Gordana Vunjak Novakovic; Thomas Eschenhagen; Christine Mummery
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

3.  G alpha(q)-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C.

Authors:  Ricky Malhotra; Karen M D'Souza; Michelle L Staron; Konstantin G Birukov; Ilona Bodi; Shahab A Akhter
Journal:  J Biol Chem       Date:  2010-03-01       Impact factor: 5.157

4.  Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion.

Authors:  Wei Yue; Koji Abe; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

Review 5.  Patching the heart: cardiac repair from within and outside.

Authors:  Lei Ye; Wolfram-Hubertus Zimmermann; Daniel J Garry; Jianyi Zhang
Journal:  Circ Res       Date:  2013-09-13       Impact factor: 17.367

6.  Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology.

Authors:  Sebastian Schaaf; Aya Shibamiya; Marco Mewe; Alexandra Eder; Andrea Stöhr; Marc N Hirt; Thomas Rau; Wolfram-Hubertus Zimmermann; Lenard Conradi; Thomas Eschenhagen; Arne Hansen
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

7.  Regulation of NADPH oxidase 5 by protein kinase C isoforms.

Authors:  Feng Chen; Yanfang Yu; Steven Haigh; John Johnson; Rudolf Lucas; David W Stepp; David J R Fulton
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

8.  Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.

Authors:  Qinghang Liu; Xiongwen Chen; Scott M Macdonnell; Evangelia G Kranias; John N Lorenz; Michael Leitges; Steven R Houser; Jeffery D Molkentin
Journal:  Circ Res       Date:  2009-06-25       Impact factor: 17.367

Review 9.  With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure.

Authors:  Jeffery D Molkentin; Jeffrey Robbins
Journal:  J Mol Cell Cardiol       Date:  2008-09-19       Impact factor: 5.000

10.  Inducible and myocyte-specific inhibition of PKCalpha enhances cardiac contractility and protects against infarction-induced heart failure.

Authors:  Michael Hambleton; Allen York; Michelle A Sargent; Robert A Kaiser; John N Lorenz; Jeffrey Robbins; Jeffery D Molkentin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-10-05       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.